Cleary Gottlieb Ranked No. 1 in GCR’s 2018 ‘Global Elite’

Cleary Gottlieb’s antitrust practice was ranked No. 1 among the “Global Elite” by Global Competition Review in the 18th edition of the GCR 100.

Cleary’s “consistent strengths across the board” in mergers, cartel defense, non-cartel conduct investigations, and litigation, and the group’s work in “uniquely headline-grabbing matters” helped it surpass all other firms in the rankings this year. In addition to the overall top ranking, Cleary was also ranked No. 1 in cartels and litigation and No. 2 for mergers.

Cleary’s antitrust work in several high-profile matters were mentioned in GCR’s profile, including:

• Dow Chemical’s $130 billion merger of equals with DuPont. 
• Abbott Laboratories’ $25 billion acquisition of St Jude Medical.
• IMS Health’s $17.6 billion merger of equals with Quintiles.
• Plaintiffs cases against “hard-to-sue” entities such as those for Teladoc and New York University Hospitals Center.
• Auto parts makers Aisin Seiki, Asahi Glass, Faurecia, NSK, Omron, and Valeo in private litigation.
• Major banks in benchmark probes in the U.S. and UK.

The “Global Elite” is Global Competition Review’s definitive list of the top 25 global law firms for competition, providing a quantitative and qualitative analysis of the law firms doing the most important antitrust work around the world.

For more information on the “Global Elite” and the 2018 edition of the GCR 100, visit GCR’s website.